Latest Ratios: P/E Ratio -13.5x · EV/EBITDA N/A · ROE -55.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $654M | $172M | $62M | $120M | $32M | $13M | — | — |
| Enterprise Value | $561M | $80M | $46M | $102M | $18M | $-4519983 | — | — |
| P/E Ratio → | -13.51 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.22 | 1.84 | 4.70 | 7.41 | 2.42 | 0.73 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -55.0% | -55.0% | -146.8% | -105.1% | -52.8% | -367.8% | — | — |
| ROA | -46.1% | -46.1% | -100.8% | -88.6% | -49.7% | -260.3% | -154.9% | -103.2% |
| ROIC | -2169.8% | -2169.8% | — | — | -10389.5% | -256.3% | — | — |
| ROCE | -49.9% | -49.9% | -148.9% | -108.2% | -52.0% | -20.4% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.08 | — | — | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -1.25 | -1.08 | -1.02 | -0.98 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -16537.12 | -134.54 | -4.45 | -7.66 |
Net cash position: cash ($94M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.01 | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Quick Ratio | 10.01 | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Cash Ratio | 9.93 | 9.93 | 2.04 | 4.70 | 10.55 | 87.33 | 0.07 | 0.16 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — |
| Shares Outstanding | — | $33M | $28M | $17M | $14M | $4M | $8M | $3M |
Clinical trial execution risk
Based on reported figures, IMMX trades at a P/B of 3.51, which appears to reflect a significant complexity discount compared to larger oncology peers, as investors struggle to reconcile the dual-platform risk of the TSTx small-molecule pipeline and the NXC-201 cell therapy subsidiary.
The current valuation multiple suggests that the market is heavily discounting the company's intangible assets, likely due to the inherent uncertainty of clinical-stage biotechnology. Investors should monitor whether the successful progression of NXC-201 can catalyze a re-rating toward the higher multiples observed in more specialized CAR-T peers.
As reported in financial statements, IMMX's ROIC has remained deeply negative, reaching -2.3% in 2026Q1, which is a structural outcome for a pre-revenue entity where capital is deployed into non-productive research assets rather than revenue-generating operations.
The persistent decay in return metrics is not indicative of operational failure but rather the high-cost nature of clinical trial execution. Analysts should interpret these figures as a measure of capital intensity rather than management efficiency, as the company has yet to reach the commercialization stage.
According to recent SEC filings, IMMX maintains a current ratio of 8.76 as of 2026Q1, providing a robust liquidity cushion that appears to insulate the firm from immediate solvency risks while it continues to fund high-cost research and development activities for its oncology pipeline.
This liquidity position is unusually strong for a clinical-stage biotech, suggesting that management has successfully prioritized balance sheet preservation. However, investors should monitor the burn rate closely, as the high current ratio may rapidly contract if clinical trial costs accelerate during Phase 2 expansion.
Based on the company's reported figures, IMMX maintains a negligible D/E ratio of 0.01%, indicating a strategic preference for equity-based financing that avoids the interest burden and restrictive covenants typically associated with debt in the volatile biotechnology sector.
The lack of leverage is a prudent choice given the company's pre-revenue status and the high risk of its clinical pipeline. This conservative capital structure provides management with maximum flexibility to pursue strategic partnerships without the constraints of debt service obligations.
As indicated by historical data, the most commonly misapplied ratio for IMMX is the P/E multiple, which obscures the company's true value by focusing on net losses that are a direct result of necessary R&D investment rather than operational inefficiency.
Investors should instead utilize a sum-of-the-parts valuation or cash-runway analysis to assess the company's progress. Relying on P/E or EBITDA multiples in this context is fundamentally flawed, as these metrics penalize the very research spending that is required to generate future clinical value.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMMX stock.
Immix Biopharma, Inc.'s current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.
Immix Biopharma, Inc.'s return on equity (ROE) is -55.0%. The historical average is -145.5%.
Based on historical data, Immix Biopharma, Inc. is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.